Equities analysts expect Aptevo Therapeutics Inc (NASDAQ:APVO) to report earnings of ($0.36) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Aptevo Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.46). Aptevo Therapeutics reported earnings of ($0.56) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 35.7%. The firm is scheduled to issue its next earnings results on Wednesday, November 13th.
According to Zacks, analysts expect that Aptevo Therapeutics will report full year earnings of ($1.39) per share for the current year, with EPS estimates ranging from ($1.88) to ($1.10). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.07) to ($0.84). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover Aptevo Therapeutics.
Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Friday, August 9th. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The firm had revenue of $7.36 million during the quarter, compared to the consensus estimate of $6.95 million. Aptevo Therapeutics had a negative return on equity of 137.50% and a negative net margin of 195.95%.
Several analysts have recently commented on the company. Zacks Investment Research raised Aptevo Therapeutics from a “sell” rating to a “buy” rating and set a $0.75 price objective for the company in a research note on Tuesday. Roth Capital reissued a “buy” rating on shares of Aptevo Therapeutics in a research note on Thursday, May 23rd. Finally, ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Five equities research analysts have rated the stock with a buy rating, Aptevo Therapeutics currently has an average rating of “Buy” and an average price target of $7.81.
In other Aptevo Therapeutics news, Director Fuad El-Hibri purchased 30,000 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The stock was bought at an average cost of $0.89 per share, with a total value of $26,700.00. Following the completion of the transaction, the director now owns 959,521 shares of the company’s stock, valued at approximately $853,973.69. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marvin L. White purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average cost of $0.88 per share, with a total value of $44,000.00. Following the completion of the transaction, the chief executive officer now directly owns 293,603 shares of the company’s stock, valued at approximately $258,370.64. The disclosure for this purchase can be found here. Insiders have purchased 416,380 shares of company stock valued at $340,044 over the last ninety days. 11.74% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its holdings in Aptevo Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock worth $1,831,000 after acquiring an additional 16,482 shares during the last quarter. Deutsche Bank AG raised its holdings in Aptevo Therapeutics by 251.7% in the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock worth $419,000 after acquiring an additional 236,300 shares during the last quarter. Marshall Wace LLP purchased a new position in Aptevo Therapeutics in the 1st quarter worth approximately $33,000. Acadian Asset Management LLC raised its holdings in Aptevo Therapeutics by 312.8% in the 2nd quarter. Acadian Asset Management LLC now owns 632,507 shares of the biotechnology company’s stock worth $560,000 after acquiring an additional 479,278 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Aptevo Therapeutics by 256.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 56,620 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 40,728 shares during the last quarter. 36.37% of the stock is owned by institutional investors and hedge funds.
Shares of Aptevo Therapeutics stock traded up $0.02 on Friday, hitting $0.76. The company had a trading volume of 5,987 shares, compared to its average volume of 580,831. The firm has a market capitalization of $32.71 million, a PE ratio of -0.32 and a beta of 2.39. Aptevo Therapeutics has a 1 year low of $0.49 and a 1 year high of $5.80. The stock’s 50 day simple moving average is $0.88. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.15 and a quick ratio of 2.91.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Recommended Story: What are popular range trading strategies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.